Stock NEXI NEXIMMUNE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases NexImmune, Inc.

Equities

NEXI

US65344D2080

Market Closed - Nasdaq
Other stock markets
 02:00:00 10/05/2024 am IST 		5-day change 1st Jan Change
3.46 USD +2.37% Intraday chart for NexImmune, Inc. +10.90% +55.86%
17/04 North American Morning Briefing : Stock Futures -2- DJ
16/04 NexImmune, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
AQ
Bull Run 2024: Biopharma Healthcare Stocks Surge, Gaining Momentum: DYAI, ABVC, FWBI, VTAK, NEXI
AQ
Neximmune : Failure to Satisfy Listing Rule - Form 8-K
PU
NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes
AQ
NexImmune Announces Presentations at The Society for Immunotherapy of Cancer’s 38th Annual Meeting
GL
NexImmune Announces Presentations at The Society for Immunotherapy of Cancer’s 38th Annual Meeting
AQ
NexImmune Announces 1-for-25 Reverse Stock Split
GL
NexImmune Announces 1-for-25 Reverse Stock Split
AQ
NexImmune Announces Workforce Reduction to Enable Continued AIMTM Nanoparticle Platform Development Strategy
GL
NexImmune Announces Workforce Reduction to Enable Continued AIMTM Nanoparticle Platform Development Strategy
AQ
NexImmune Reports Second Quarter 2023 Financial Results and Provides Business Updates
GL
NexImmune : Robust immune response with clinical activity at the highest dose level with one patient achieving no evidence of disease 7 months post-infusion with NEXI-001 - Form 8-K
PU
NexImmune Presents Initial Positive Data from the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post Allo-HSCT AML at the American Society of Clinical Oncology 2023 Annual Meeting
AQ
NexImmune Announces Poster Presentation at the 2023 FOCIS Annual Meeting
AQ
NEXIMMUNE, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)
AQ
NexImmune Reports First Quarter 2023 Financial Results and Provides Business Updates
GL
NEXIMMUNE, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events (form 8-K)
AQ
NexImmune Announces Presentation of Phase 1/2 Clinical Data at the 2023 American Society of Clinical Oncology Annual Meeting
AQ
NEXIMMUNE, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)
AQ
NexImmune Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NEXI Stock
  4. News NexImmune, Inc.
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW